CH BIOTECH SER (08037) announced its interim financial results. The company's owners reported a net loss of HK$32.06 million, a decrease of 59.95% year-on-year.

CH BIOTECH SER (08037) announced its performance for the midterm of 2025, with a revenue of 38.872 million Hong Kong dollars, a year-on-year increase of 19.79%; the company's attributable loss was 32.006 million Hong Kong dollars, a year-on-year narrowing of 59.95%; loss per share was 0.033 Hong Kong dollars. The announcement stated that the main reason for the improvement in losses was the successful implementation of cost control measures by the company, leading to an increase in gross profit margin and reduction in administrative expenses, as well as insurance claims for damage caused by heavy rain in Hainan construction sites in 2024, resulting in compensation income of approximately 13.7 million Hong Kong dollars.